116 related articles for article (PubMed ID: 22663297)
1. Peptide-drug conjugate linked via a disulfide bond for kidney targeted drug delivery.
Geng Q; Sun X; Gong T; Zhang ZR
Bioconjug Chem; 2012 Jun; 23(6):1200-10. PubMed ID: 22663297
[TBL] [Abstract][Full Text] [Related]
2. Specific delivery of captopril to the kidney with the prodrug captopril-lysozyme.
Kok RJ; Grijpstra F; Walthuis RB; Moolenaar F; de Zeeuw D; Meijer DK
J Pharmacol Exp Ther; 1999 Jan; 288(1):281-5. PubMed ID: 9862782
[TBL] [Abstract][Full Text] [Related]
3. l-Serine-modified polyamidoamine dendrimer as a highly potent renal targeting drug carrier.
Matsuura S; Katsumi H; Suzuki H; Hirai N; Hayashi H; Koshino K; Higuchi T; Yagi Y; Kimura H; Sakane T; Yamamoto A
Proc Natl Acad Sci U S A; 2018 Oct; 115(41):10511-10516. PubMed ID: 30249662
[TBL] [Abstract][Full Text] [Related]
4. Renal targeting of captopril using captopril-lysozyme conjugate enhances its antiproteinuric effect in adriamycin-induced nephrosis.
Windt WA; Prakash J; Kok RJ; Moolenaar F; Kluppel CA; de Zeeuw D; van Dokkum RP; Henning RH
J Renin Angiotensin Aldosterone Syst; 2004 Dec; 5(4):197-202. PubMed ID: 15803438
[TBL] [Abstract][Full Text] [Related]
5. Renal-selective delivery and angiotensin-converting enzyme inhibition by subcutaneously administered captopril-lysozyme.
Prakash J; van Loenen-Weemaes AM; Haas M; Proost JH; Meijer DK; Moolenaar F; Poelstra K; Kok RJ
Drug Metab Dispos; 2005 May; 33(5):683-8. PubMed ID: 15673598
[TBL] [Abstract][Full Text] [Related]
6. Characterization of in vivo disulfide-reduction mediated drug release in mouse kidneys.
Yang JJ; Kularatne SA; Chen X; Low PS; Wang E
Mol Pharm; 2012 Feb; 9(2):310-7. PubMed ID: 22171616
[TBL] [Abstract][Full Text] [Related]
7. Targeting of captopril to the kidney reduces renal angiotensin-converting enzyme activity without affecting systemic blood pressure.
Kok RJ; Haverdings RF; Grijpstra F; Koiter J; Moolenaar F; de Zeeuw D; Meijer DK
J Pharmacol Exp Ther; 2002 Jun; 301(3):1139-43. PubMed ID: 12023548
[TBL] [Abstract][Full Text] [Related]
8. Renal targeting of captopril selectively enhances the intrarenal over the systemic effects of ACE inhibition in rats.
Haverdings RF; Haas M; Navis G; Van Loenen-Weemaes AM; Meijer DK; De Zeeuw D; Moolenaar F
Br J Pharmacol; 2002 Aug; 136(8):1107-16. PubMed ID: 12163343
[TBL] [Abstract][Full Text] [Related]
9. Enhancement of anti-tumor activity of hybrid peptide in conjugation with carboxymethyl dextran via disulfide linkers.
Gaowa A; Horibe T; Kohno M; Tabata Y; Harada H; Hiraoka M; Kawakami K
Eur J Pharm Biopharm; 2015 May; 92():228-36. PubMed ID: 25801495
[TBL] [Abstract][Full Text] [Related]
10. Metabolism of protein conjugate of desacetyl-alacepril and its effect on angiotensin converting enzyme in renal hypertensive rats.
Matsumoto K; Nambu K; Fujii T; Takeyama K; Miyazaki H; Hashimoto M
Arzneimittelforschung; 1986; 36(1):52-4. PubMed ID: 3006711
[TBL] [Abstract][Full Text] [Related]
11. Renal Targeting: Peptide-Based Drug Delivery to Proximal Tubule Cells.
Wischnjow A; Sarko D; Janzer M; Kaufman C; Beijer B; Brings S; Haberkorn U; Larbig G; Kübelbeck A; Mier W
Bioconjug Chem; 2016 Apr; 27(4):1050-7. PubMed ID: 26999755
[TBL] [Abstract][Full Text] [Related]
12. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
[TBL] [Abstract][Full Text] [Related]
13. Synthesis of disulfide-cross-linked polypeptide nanogel conjugated with a near-infrared fluorescence probe for direct imaging of reduction-induced drug release.
Xing T; Mao C; Lai B; Yan L
ACS Appl Mater Interfaces; 2012 Oct; 4(10):5662-72. PubMed ID: 22974285
[TBL] [Abstract][Full Text] [Related]
14. Peptide and Low Molecular Weight Proteins Based Kidney Targeted Drug Delivery Systems.
Xu P; Zhang H; Dang R; Jiang P
Protein Pept Lett; 2018; 25(6):522-527. PubMed ID: 29848259
[TBL] [Abstract][Full Text] [Related]
15. A high-affinity peptide for nicotinic acetylcholine receptor-α1 and its potential use in pulmonary drug delivery.
Park S; Kim YJ; Jon S
J Control Release; 2014 Oct; 192():141-7. PubMed ID: 25025285
[TBL] [Abstract][Full Text] [Related]
16. In vitro-in vivo correlation and bioavailability studies of captopril from novel controlled release donut shaped tablet.
Mandal AS; Chatterjee S; Kundu S; Biswas N; Guha A; Paul S; Kuotsu K
Int J Pharm; 2011 Dec; 421(1):145-50. PubMed ID: 21945741
[TBL] [Abstract][Full Text] [Related]
17. Design of a tumor-homing cell-penetrating peptide.
Myrberg H; Zhang L; Mäe M; Langel U
Bioconjug Chem; 2008 Jan; 19(1):70-5. PubMed ID: 18001077
[TBL] [Abstract][Full Text] [Related]
18. Vesicle-to-cytosol transport of disulfide-linked cargo mediated by an amphipathic cell-penetrating peptide.
Kenien R; Shen WC; Zaro JL
J Drug Target; 2012 Nov; 20(9):793-800. PubMed ID: 22994388
[TBL] [Abstract][Full Text] [Related]
19. Effect of combining an ACE inhibitor and an angiotensin II receptor blocker on plasma and kidney tissue angiotensin II levels.
Komine N; Khang S; Wead LM; Blantz RC; Gabbai FB
Am J Kidney Dis; 2002 Jan; 39(1):159-64. PubMed ID: 11774115
[TBL] [Abstract][Full Text] [Related]
20. A novel peptide specifically targeting the vasculature of orthotopic colorectal cancer for imaging detection and drug delivery.
Li ZJ; Wu WK; Ng SS; Yu L; Li HT; Wong CC; Wu YC; Zhang L; Ren SX; Sun XG; Chan KM; Cho CH
J Control Release; 2010 Dec; 148(3):292-302. PubMed ID: 20854857
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
